Partner Content Partner Content KOL Mapping and Validation You’ve done your KOL Mapping, and you have been in a therapy area for a while. You may have gotten used to working with the same KOLs and Experts over and over again.
News ASCO: BMS hails "compelling" phase 3 celmod readout Bristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
